Wednesday, January 7, 2026 1/7/2026

Identifying Mechanisms of Resistance to SLC6AB Inhibition in CRC Liver Metastasis

Award Number: K00CA284284
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2025
PERIOD OF PERFORMANCE END DATE: 12/31/2028

Group Awards By:

View Award Description

Identifying Mechanisms of Resistance to SLC6AB Inhibition in CRC Liver Metastasis - Even though ranked as the third diagnosed cancer, colorectal cancer (CRC) is the second cause of cancer death globally. Over 70% of CRC tumors metastasize to the liver, which is a major factor in mortality. This drastically diminishes the five-year survival rate, leaving current standard of the care (surgery and chemotherapy) ineffective, due to resistance. This underlines the urgent need for new therapeutic options. The Tavazoie lab has identified a critical survival mechanism in CRC cells, where in hypoxic conditions, metastatic cells secrete creatine kinase Brain (CKB), which converts creatine to phosphocreatine using extracellular ATP. Phosphocreatine is then transferred into the cells via SLC6A8, providing an essential energy source. Inhibition of SLC6A8 with the small-molecule RGX-202 has shown encouraging results in preclinical models and early clinical trials. However, resistance to RGX-202 poses a significant challenge. Unraveling the mechanisms that CRC cells use to survive in the hypoxic liver environment and resist treatments is central for developing more effective targeted therapies. This study intends to discover the mechanisms of resistance to SLC6A8 inhibition in CRC liver metastasis using a multi-omic approach. We hypothesize that adaptive genetic and metabolic alterations drive resistance to RGX- 202, which can be identified and targeted. One specific aim with three sub aims will address this hypothesis: Aim 1: To identify mechanisms of resistance to SLC6A8 inhibition in CRC liver metastasis. Aim 1a: Conduct in vivo CRISPR-Cas9 screen in RGX-202-01 sensitive and resistant CRC liver metastasis model cells to identify genes that cause resistance to SLC6A8 inhibitor in hypoxic liver microenvironment. Aim 1 b: Define metabolic alterations in RGX-202-resistant CRC tumors and identify metabolic pathways that contribute to CRC liver metastases. Aim 1c: Establish the molecular corelates of CRC resistance to RGX-202 using unbiased genomic approaches. Significance of this research is to delineate the genetic and metabolic mechanisms by which CRC cells survive in the hypoxic liver environment and become resistant to SLC6A8 inhibition. This study is innovative as it incorporates in vivo CRISPR screens, metabolomics, and transcriptomics to identify resistance mechanisms and establishes new paradigms for treating therapy-resistant CRC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $91,890 )
2026	2026	ROCKEFELLER UNIVERSITY	1230 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	000	4	12/16/2025	NON-COMPETING CONTINUATION	$91,890
														Subtotal = $91,890

Issue Date FY: 2025 ( Subtotal = $100,923 )
2025	2025	ROCKEFELLER UNIVERSITY	1230 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Research Manpower	000	3	12/20/2024	EXTENSION WITH OR WITHOUT FUNDS	$100,923
														Subtotal = $100,923

Grand Total All Awards = $192,813

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Identifying Mechanisms of Resistance to SLC6AB Inhibition in CRC Liver Metastasis

Award Number: K00CA284284

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2025

PERIOD OF PERFORMANCE END DATE: 12/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer